Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
- Citation:
- Leukemia vol 35 (9) 2539-51
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Pharmas:
- Novartis
- Grants:
- U10CA180821, U10CA180882, U24CA196171, U10CA032291, U10CA041287, U10CA077651, U10CA077658, U10CA180791, U10CA180836, U10CA180850, U10CA180867, UG1CA233338, U10CA180863 (CCTG), U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG).
- Corr. Author:
- Authors:
- Richard A. Larson Sumithra J. Mandrekar Lucas J. Huebner Ben L. Sanford Kristina Laumann Susan Geyer Clara D. Bloomfield Christian Thiede Thomas W. Prior Konstanze Döhner Guido Marcucci Maria Teresa Voso Rebecca B. Klisovic Ilene Galinsky Andrew H. Wei Jorge Sierra Miguel A. Sanz Joseph M. Brandwein Theo de Witte Dietger Niederwieser Frederick R. Appelbaum Bruno C. Medeiros Martin S. Tallman Jürgen Krauter Richard F. Schlenk Arnold Ganser Hubert Serve Gerhard Ehninger Sergio Amadori Insa Gathmann Hartmut Döhner Richard M. Stone
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007
- Study
- CALGB-10603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: